Home Biosimilar Antibodies Immunology & Inflammation CD markers Selicrelumab (Anti-TNFRSF5 / CD40)
For research use only. Not for use in humans.

Selicrelumab (Anti-TNFRSF5 / CD40)

Synonyms: CD40， TNFRSF5

Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD.

Selicrelumab (Anti-TNFRSF5 / CD40)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD.
References

Product Details

CAS No. 1622140-49-1
Molecular Weight 146.2
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05849480 RECRUITING Drug: oxaliplatin|Drug: capecitabine Biliary Cancer; Bile Duct Cancer; Cancer of the Bile Duct National Cancer Institute (NCI) 2024-05-08 PHASE1; PHASE2
NCT03424005 RECRUITING Drug: Capecitabine|Drug: Atezolizumab|Drug: Ipatasertib|Drug Metastatic Breast Cancer Hoffmann-La Roche 2018-03-30 PHASE1; PHASE2
NCT06347705 RECRUITING Prostate Cancer Memorial Sloan Kettering Cancer Center 2024-03-28 PHASE2
NCT06305286 ACTIVE_NOT_RECRUITING Drug: Islet transplantation with Tegoprubart (AT-1501) immun Type 1 Diabetes Mellitus University of Chicago 2024-03-04 PHASE1; PHASE2
NCT07166601 RECRUITING Drug: mFOLFIRINOX Advanced Solid Tumor EMD Serono Research & Development Institute, Inc. 2025-10-10 PHASE1
NCT07036380 RECRUITING Drug: MP0317 + Gemcitabine + Cisplatine + Durvalumab|Drug: G Advanced Biliary Tract Carcinoma Centre Hospitalier Universitaire de Besancon 2025-12-22 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.